---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-055650"
form_type: "8-K"
ticker: "ASMB"
cik: "0001426800"
company_name: "ASSEMBLY BIOSCIENCES, INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T09:35:47.135230+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Assembly Bio reports Q1 net loss $9.1M; CTAs cleared for two clinical trials

## Summary
- Net loss narrowed to $9.1M ($1.66/sh) from $19.0M ($4.46) YoY; cash $113M funds ops into H2 2025.
- CTAs cleared for Phase 1a/1b of ABI-5366 (genital herpes) and Phase 1b of ABI-4334 (HBV); both on track by mid-2024.
- Interim data expected: ABI-5366 Ph1a in Q3 2024; ABI-4334 Ph1b by year-end 2024.
- Two more candidates (ABI-1179 and ABI-6250) expected to enter clinic by end of 2024.
- Revenue from Gilead collaboration $5.8M in Q1 2024 vs $0 prior year.

## SEC filing metadata
- accession: 0000950170-24-055650
- form_type: 8-K
- ticker: ASMB
- cik: 0001426800
- company_name: ASSEMBLY BIOSCIENCES, INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1426800/000095017024055650/0000950170-24-055650-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1426800/000095017024055650/asmb-20240508.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-055650
- JSON: https://secwatch.observer/filing/0000950170-24-055650.json
- Plain text: https://secwatch.observer/filing/0000950170-24-055650.txt

## Key facts
- Earnings Releases
  ASSEMBLY BIOSCIENCES, INC. reported first quarter ended March 31, 2024 results: revenue $5.8 million, net income $9.1 million, EPS $1.66 per basic and diluted share.
  - Period: first quarter ended March 31, 2024
  - Revenue: $5.8 million
  - Net income: $9.1 million
  - EPS: $1.66 per basic and diluted share
  - Result: reported results
  source text: to $130.2 million as of December 31, 2023. Assembly Bio’s cash position is projected to fund operations into the second half of 2025. • Revenues from collaborative research were $5.8 million for the three months ended March 31, 2024. There was no revenue recognized for the same period in 2023. Revenue for the three months ended March 31, 2024 consists of amounts
  evidence_url: https://www.sec.gov/Archives/edgar/data/1426800/000095017024055650/0000950170-24-055650-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.